Literature DB >> 1653147

Opioid binding in the rostral hypothalamus is reduced following lesion of the ventral noradrenergic tract in female rats.

R G Dyer1, N Parvizi, S Hollingsworth, S Mansfield, R P Heavens, R J Bicknell, D J Sirinathsinghji.   

Abstract

Experiments were undertaken to establish whether opioid receptors exert a direct presynaptic influence on noradrenergic (NA) terminals in the preoptic/anterior hypothalamus (PO/AH) of the female rat. Thus, opioid binding studies were performed in rats with lesions of the ventral NA tract (VNAT; the main NA projection to the hypothalamus) to assess whether a loss of NA terminals may also result in a decrease in opioid binding in the PO/AH. In the first experiment, unilateral electrolytic lesions of the VNAT caused a significant reduction in both the NA content and specific [3H]-diprenorphine binding to membrane homogenates in the ipsilateral PO/AH. In the second experiment bilateral 6-hydroxydopamine (6-OHDA)-induced lesions of the VNAT caused a significant reduction in NA levels in the PO/AH as well as significant decreases in the density of [3H]-diprenorphine binding to tissue sections of the PO/AH when compared to control animals. These results strongly suggest that the NA input to the PO/AH is regulated by endogenous opioid peptides, and provide an anatomical substrate to explain opioid-NA interactions in the control of gonadotrophin releasing hormone (GnRH) and gonadotrophin secretion.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1653147     DOI: 10.1007/bf00230005

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  23 in total

1.  Hypersensitivity to noradrenaline in cortex after chronic morphine: relevance to tolerance and dependence.

Authors:  C Llorens; M P Martres; M Baudry; J C Schwartz
Journal:  Nature       Date:  1978-08-10       Impact factor: 49.962

2.  Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--I. Behavioural, neurochemical and histological characterization of the lesion.

Authors:  D J Sirinathsinghji; R P Heavens; S J Richards; I J Beresford; M D Hall
Journal:  Neuroscience       Date:  1988-10       Impact factor: 3.590

3.  The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties.

Authors:  J Magnan; S J Paterson; A Tavani; H W Kosterlitz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-06       Impact factor: 3.000

4.  Evidence for noradrenergic mediation of opioid effects on luteinizing hormone secretion.

Authors:  S P Kalra; J W Simpkins
Journal:  Endocrinology       Date:  1981-09       Impact factor: 4.736

5.  Morphine and beta-endorphin inhibit release of noradrenaline from cerebral cortex but not of dopamine from rat striatum.

Authors:  S Arbilla; S Z Langer
Journal:  Nature       Date:  1978-02-09       Impact factor: 49.962

6.  Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain.

Authors:  A Mansour; H Khachaturian; M E Lewis; H Akil; S J Watson
Journal:  J Neurosci       Date:  1987-08       Impact factor: 6.167

7.  Effects of naloxone on catecholamine and LHRH release from the perifused hypothalamus of the steroid-primed rat.

Authors:  C A Leadem; W R Crowley; J W Simpkins; S P Kalra
Journal:  Neuroendocrinology       Date:  1985-06       Impact factor: 4.914

8.  Gonadotropin-releasing hormone (GnRH) neurons and pathways in the rat brain.

Authors:  I Merchenthaler; T Görcs; G Sétáló; P Petrusz; B Flerkó
Journal:  Cell Tissue Res       Date:  1984       Impact factor: 5.249

9.  Opioid peptides inhibit the release of noradrenaline from slices of rat medial preoptic area.

Authors:  F J Diez-Guerra; S Augood; P C Emson; R G Dyer
Journal:  Exp Brain Res       Date:  1987       Impact factor: 1.972

10.  Effects of morphine on luteinizing hormone secretion and catecholamine turnover in the hypothalamus of estrogen-treated rats.

Authors:  A Akabori; C A Barraclough
Journal:  Brain Res       Date:  1986-01-08       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.